key: cord-0871741-jg8awpxn
authors: Cantini, L.; Mentrasti, G.; Siena, S.; Pasello, G.; Galetti, A.; Caliman, E.; Rocco, D.; Adamo, V.; Genova, C.; Morabito, A.; Gori, S.; Rijavec, E.; Chiari, R.; Oldani, S.; Caglio, A.; De Tursi, M.; Cortellini, A.; Morgillo, F.; Bennati, C.; Guida, A.; Spinelli, G. P.; Emili, R.; Roca, E.; Indini, A.; De Toma, A.; Vallini, I.; D'Emilio, V.; Cognigni, V.; Pecci, F.; Migliore, A.; Della Gravara, L.; Frega, S.; Zullo, L.; Zattarin, E.; Citarella, F.; Russo, A.; Fancelli, S.; Oresti, S.; Berardi, R.
title: OA01.02 Impact of COVID-19 Outbreak on Lung Cancer Diagnosis and Continuum of Care: Data From an Italian Multicenter Study
date: 2021-10-31
journal: Journal of Thoracic Oncology
DOI: 10.1016/j.jtho.2021.08.035
sha: 965aa130a473f4a2f7c4f71799ce62e3ed920e0e
doc_id: 871741
cord_uid: jg8awpxn

nan

Introduction: Patients with lung cancer (LC) were reported to have a high case fatality rate (30-40%) from SARS-CoV-2 infection, raising the question of whether LC patients mount a weaker antibody response to natural infection and/or vaccination, compared to healthy controls (HCs). We previously analyzed antibody responses to SARS-CoV-2 mRNA vaccination in several hundred healthy individuals, stratified by previous SARS-CoV-2 infection status. Using a validated enzyme-linked immunosorbent assay (ELISA) to the full-length spike protein (PMC8183627, PMC7235504), we found strong responses to infection and a robust neutralizing antibody response to vaccination. We compare these results to data from individuals diagnosed with LC undergoing different types of cancer treatment. Methods: This is an ongoing, prospective, control-matched longitudinal cohort study of 750 LC patients in all stages with or without previous SARS-CoV-2 infection and/or vaccination, comparing SARS-CoV-2 antibody titers at baseline (time of enrollment) and at 3-, 6-, 12-and 24-month intervals. We examine the quality, magnitude, and duration of the SARS-CoV-2 antibody titers against the full-length spike protein compared to the matched (age, tobacco history, sex and ethnicity) HC cohort. Types of Analysis and Data Reporting: ELISAs are performed in a CLIAcertified laboratory using an FDA-approved antibody assay along with other well-established, research-grade assays. We hypothesized that LC patients have a weaker antibody response to SARS-Cov-2 infection and/or vaccination due to cancer or its treatment compared to matched HCs. The non-parametric KruskaleWallis test was used to test this hypothesis. If confirmed, a tailored vaccination program would be necessary to ensure immune protection in patient with LC. Results: 111 LC patients have been enrolled to date; with 78 receiving at least one vaccination and 33 unvaccinated. Median age is 69, with 58% female. 39 patients were fully vaccinated (defined as 14+ days after second vaccination). Partially vaccinated (after 1 st vaccine dose) LC patients had a lower median antibody level than partially vaccinated HCs (p¼0.01). Fully vaccinated LC patients had substantial antibody titers but a lower median antibody level than fully vaccinated HCs (p¼0.01) with a subset not raising large antibody titers. Especially important were the 30% of partially vaccinated LC patients who did not develop neutralizing antibodies. To date, there were no significant differences in median antibody levels in LC patients by gender, smoking status, age (< or > 65 years old), or treatment (with or without chemotherapy, immune checkpoint inhibitors, or targeted therapy). Conclusion: While most (w70%+) of LC patients mounted a good antibody response to vaccination, a subgroup had significantly lower anti-spike antibody/neutralizing levels compared to controls. Further studies are required to evaluate the role of further boost vaccinations in this patient population with a particular focus on patients not producing neutralizing antibodies to further understand the lack of response. We will continue to analyze the effect of systemic anti-cancer therapies as more data becomes available. Keywords: SARS-CoV-2, lung cancer, covid-19 OA01.02 Impact of COVID-19 Outbreak on Lung Cancer Diagnosis and Continuum of Care: Data From an Italian Multicenter Study population. Aim of this multicenter Italian study is to assess whether the COVID-19 outbreak has impacted on access to cancer diagnosis, staging and treatment for LC patients after March 2020 compared to pre-pandemic time. Methods: Medical records of all consecutive newly diagnosed LC pts referred to 24 Italian Oncology Departments between March and December 2020 were reviewed. Access rate (number of pts/ days) and temporal intervals between date of symptoms onset, radiological diagnosis, cytohistological diagnosis, treatment start, and first radiological revaluation were computed and compared with those of the same period in 2019. Differences between the two years were analyzed using Fisher's exact test or chi-square test for categorical variables and unpaired Student t test, or the Mann-Whitney U test for continuous variables. Results: A slight reduction in newly diagnosed LC cases was seen when compared with 2019 (1381 vs 1443, access rate ratio ¼ 0.95, p ¼ 0.86). However, newly diagnosed LC patients in 2020 were more likely to have advanced disease (75% vs 69%, p < 0.01).

Other clinical and tumor characteristics were similar regardless of the year, with the only exception of the number of current smokers, which was higher in 2020 (38% vs 34%, p ¼ 0.02). Looking at pts management, no differences emerged in terms of interval between symptoms onset and radiological diagnosis (median 26 vs 25 days, p ¼ 0.52), symptoms onset and cytohistological diagnosis (47 vs 45 days, p ¼ 0.36), symptoms onset and treatment start (median 76 vs 77 days, p ¼ 0.93), treatment start and first radiological revaluation (71 vs 71 days, p¼ 0.36). The interval between cytohistological diagnosis and treatment start was even shorter in 2020 (30 vs 33 days, p < 0.01). Conclusion: Despite COVID-19 had unprecedentedly changed the face of cancer care, our study provides a thorough insight on the effectiveness of the measures adopted by Italian Oncology Departments to optimally address quality of care issues and lung cancer patient's likelihood of receiving timely diagnosis and treatment. As COVID-19 shows no sign of abating, our results may prove even more valuable to guide further steps in the ongoing pandemic. Future investigations will offer a more exhaustive picture on the efforts made to contain the coronavirus tidal wave also in other cancer settings. Keywords: continuum of care, covid-19, lung cancer OA01.03 Immune Checkpoint Inhibitor Dose Adaptation During the COVID-19 Pandemic in Non-Small Cell Lung Cancere a Single-Center Experience L. Hijmering-Kappelle, T.j.n. Hiltermann, F. Bensch University Medical Center Groningen, Groningen/NL Introduction: The COVID-19 pandemic forced all oncologists worldwide to reduce patient contacts to decrease risk of exposure to the virus, and to reallocate resources to provide necessary COVID-19 care. We realized such a reduction of site-visits in our center by adapting the dosing schedules of nivolumab and pembrolizumab monotherapy and consolidation therapy or adjuvant durvalumab for patients with stage III and IV non-small cell lung cancer (NSCLC). Here we report the toxicity of the adapted dose versus the standard dose schedule in a real-world NSCLC population. Methods: We retrospectively analyzed data of all patients with NSCLC, age 18 years, who were treated with dose-adapted ICI consolidation therapy (stage III disease) or adapted dose ICI mono-or consolidation therapy (stage IV disease) between March 1 2020 and January 31 2021 in our center. Dose adaptation was defined as followed: Pembrolizumab mono-or consolidation therapy was administered every 6 weeks at a dose of 400 mg (1), nivolumab every 4 weeks at a dose of 480 mg (2), and durvalumab every 4 weeks at a dose of 1500 mg (3). Toxicity of the adapted dose group was compared to consecutive patients who had received standard dose ICI between January 1 2019 and February 28 2020 in our center. Results: A total of 108 patients received dose-adapted ICI treatment. Baseline characteristics, including ECOG performance score, NSCLC subtype and PD-L1 expression, of the adapted dose group were similar to the standard group of 83 patients, except for a larger number of patients treated with durvalumab in the adapted dose group. A total of 229 adverse events were reported in the adapted dose group, versus 114 in the standard dose group. Low grade skin toxicity, fatigue, endocrinopathies and gastrointestinal toxicities were the most frequently registered adverse events with an occurrence of 33.7%, 26.5%, 20.5% and 24.1% in the standard dose group, and 70.4%, 46.3%, 37% and 23.1% in the adapted dose group. In both groups a similar number of high grade events was reported, 19/114 in the standard dose group and 18/229 in the dose adapted group. Ultimately, 7 patients (6.4%) of the dose adapted group were reduced to standard dose because of toxicity, and in 3 (2.7%) patients ICI treatment was discontinued. In the standard dose group a total of 10 patients (12%) were discontinued from treatment due to toxicity. Short-term treatment interruption occurred in 11 (13.2%) patients receiving standard dose and in 15 (13.9%) patients who received the adapted dose. Conclusion: In the adapted dose group low grade adverse events were observed more frequently compared to the standard dose group. During dose escalation, however, there was no increase in toxicity leading to dose reduction and/or discontinuation of treatment compared to the standard dose group. Based on this data, ICI dose adaptation seems a save strategy to decrease the number of visits to the oncology unit during the COVID-19 pandemic. Limitations of this analysis include its retrospective character and potential reporting bias, especially of low-grade adverse events in the adjusted dose group. 

Hongkong/CN Introduction: Patient reported outcomes is limited in Chinese lung cancer patients with radiation therapy (RT) to thorax. The purpose of this study is to investigate Patient Reported Outcome Measures (PROM) at baseline and end for RT in lung cancer patients receiving RT to thorax. Methods: This is a prospective study of quality of life

a total of 22 patients enrolled and had completed PROMIS questionnaire at both baseline and end of RT. The median age was 64 (range 34-82), nineteen were men. There was 18 and 4 non-small cell lung cancer and small cell lung cancer, respectively. Ten (45.5%) had concurrent chemotherapy and 12 (54.5%) had RT alone. Ten (45.5%) received radical RT, eleven (50%) received consolidative or palliative RT and one (4.5%) received adjuvant RT. The median dose was 50Gy (range 20-60Gy). [Office1] For the seven domain teams, physical function, anxiety, depression, fatigue, sleep disturbance